Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on TradePub.com for readers like you. LEARN MORE
Lessons Learned from a National Program to Improve Access to Cancer Testing and Treatment During COVID-19
Request Your Free White Paper Now:

"Lessons Learned from a National Program to Improve Access to Cancer Testing and Treatment During COVID-19"

COVID-19 created a crisis for cancer patients who have faced extraordinary uncertainty since March 2020. Global headlines continue to report on cancer surgery cancellations, as well as patients presenting with more advanced stages of disease because of delayed diagnosis. Cancer patients have an estimated two-fold increased risk of contracting COVID-19 and a three-fold risk of dying compared to the general population.

Some tissue biopsy delays can be offset by a minimally invasive blood draw to enable oncologists to select targeted treatment options and monitor disease progression. Circulating tumor DNA (ctDNA) testing is already widely deployed throughout the United States but is not yet standard of care in many places in the world. In exceptional cases, for example, Canadian patients who can access this testing through an oncologist must wait for blood samples to be shipped over the border, analyzed in US labs, and then for results to arrive weeks later. This current scenario costs thousands of dollars per patient and is not accessible to all patients who would benefit.

This white paper from Canexia Health describes the key findings from a pilot project to bring ctDNA testing to over 2,000 cancer patients with advanced breast, lung, and colorectal cancer in the Canadian health system during the COVID-19 pandemic.


Offered Free by: Canexia Health
See All Resources from: Canexia Health

Recommended for Professionals Like You: